Where does Pharmain Corporation rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Pharmain Corporation ranks #29,771 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Pharmain Corporation hold?

Pharmain Corporation holds 9 US utility patents granted between 2015 and 2025, spanning 4 technology areas.

What is Pharmain Corporation's Innovation Score?

Pharmain Corporation has an Innovation Score of 29.8 out of 100 (32nd percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Pharmain Corporation's patent grant rate increasing or decreasing?

Pharmain Corporation's recent grant velocity is -86% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Pharmain Corporation's patents?

Pharmain Corporation's patents average 24.7 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Pharmain Corporation patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Pharmain Corporation

Q: What technology areas does Pharmain Corporation focus on?

Pharmain Corporation's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 9 patents. Grants appear in 4 CPC subclasses total.

USPTO PatentsView assignee record - 9 granted patents across 4 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Pharmain ranks #29,771 of 49,997 tracked US assignees by granted-patent volume, with 9 patents across 4 technology areas.

#29,771
of 49,997 US assignees by volume: 32nd percentile
by Innovation Score (29.8/100): 24.7
avg claims per patent: -86%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R29771 · US Corporation #29,771 · 9 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 9 grants
MID-PACK #29,771/49,997
PHOTO-FINISH Petit Elin
CPC-NARROW A61P · 4 areas
INNOV-THIN 29.8/100
CLAIMS-DENSE 24.7 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -86% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Petit Elin Co., Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Pharmain · this assignee

30
3D Lighting… · lowest

7

What this shows Pharmain's Innovation Score is 29.8/100 (32nd percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Pharmain's grants concentrate

Pharmain Corporation is a focused PatentsView assignee: 4 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2015 (2 grants) versus a trough of 1 in 2019. By volume, Pharmain sits between Petit Elin Co., Ltd. and Piramal Pharma Limited.

Petit Elin

9
PGA Tour Enterpri…

9
Phaanix PTY

9
Pharma Foods Inte…

9
PI Industries

9
Pinnacle Seed

9
Pipl

9
Piramal Pharma

9
Pharmain ◀

9

What this shows Pharmain holds 9 patents at rank #29,724, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Pharmain

By rank, the assignees closest to #29,724 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Pharmain's primary technology class.

Pharmain's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

30 32nd percentile higher than 32% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Pharmain Corporation patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	2	22.2%
2017	2	22.2%
2018	2	22.2%
2019	1	11.1%
2020	1	11.1%
2025partial year	1	11.1%

Which technologies does Pharmain Corporation patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 9

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 9

C07K - Peptides 5

C08G - Macromolecular Compounds Obtained Otherwise Than BY Reactions Only Involving Unsaturated Carbon-to-carbon Bonds 1

Top 4 of 4 technology areas

Where it ranks

Overall rank by patents

#29,771

of 49,997 tracked assignees

Innovation Score

29.8 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Pharmain Corporation's patent record in context - here's where to go next.

Pharmain Corporation's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #29,771 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Pharmain Corporation against Petit Elin Co., Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 29.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.